POST Online Media Lite Edition


AstraZeneca appoints Aradhana Sarin as chief financial officer

Christian Fernsby |
London, England - AstraZeneca announced that it has appointed Aradhana Sarin as an executive director and chief financial officer.

Article continues below

This is conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals and effective on the later of 1 August 2021 or the date of Closing, which is expected to take place in the third quarter of 2021, subject to receipt of certain regulatory approvals.

Dr. Sarin is currently Chief Financial Officer at Alexion.

She joined Alexion in November 2017, serving as Chief Business and Strategy Officer prior to becoming Chief Financial Officer.

Dr. Sarin has more than 20 years of professional experience spanning operating roles at Alexion and advisory roles at global financial institutions, gaining extensive knowledge of global healthcare systems, capital markets and strategic transactions.

Prior to joining Alexion, she was Managing Director, Healthcare Corporate & Investment Banking, Citi Global Banking in New York where she advised clients in the life sciences and biopharmaceutical sectors.

Before that, Dr. Sarin was Managing Director, Healthcare Investment Banking, UBS, in New York and San Francisco and worked at JP Morgan in New York in the M&A Advisory and Healthcare groups.

Prior to her banking career, she trained as a medical doctor in India and spent two years practising in both India and Africa.

Dr. Sarin completed her medical training (M.B.B.S.) at the University of Delhi in India and received her MBA from Stanford Business School in the US.


New England Peptide appoints CEO and CFO
Bank of England announces executive director appointments
Philip Shapiro new chairman of ISO New England
Peter England new CEO of RAKBANK
C.R. England: David A. Kramer new executive vice president